ReviewCurrent oncology reports2010
Can anthracycline therapy for pediatric malignancies be less cardiotoxic?
Review in Current oncology reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 39 citations in OpenAlex.
- Effects of Cardiotoxins on Cardiac Stem and Progenitor Cell Populations.Frontiers in cardiovascular medicine · 2021Review
- Doxorubicin-Induced Cardiomyopathy in Children.Comprehensive Physiology · 2019Review
- Late Cardiotoxicity: Issues for Childhood Cancer Survivors.Current treatment options in cardiovascular medicine · 2016Review
- Cardiotoxicity of anthracycline therapy: current perspectives.Archives of medical science : AMS · 2016Article
- Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors.Pediatric cardiology · 2015Review
- Recurrent pulmonary synovial sarcoma effectively treated with amrubicin: A case report.Experimental and therapeutic medicine · 2015Article
- Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.Antioxidants & redox signaling · 2013Review
- Anthraquinone-2-sulfonic acid (AQ2S) is a novel neurotherapeutic agent.Cell death & disease · 2013Article
- Current and future management strategies for relapsed or progressive hepatoblastoma.Paediatric drugs · 2012Review
- Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.Future cardiology · 2012Review
- Asymmetric enzymatic glycosylation of mitoxantrone.Organic letters · 2011Article
- Cardiovascular effects in childhood cancer survivors treated with anthracyclines.Cardiology research and practice · 2011Article
- Review of cardiotoxicity in pediatric cancer patients: during and after therapy.Cardiology research and practice · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anthracyclines have a central role in the treatment of cancer in pediatric patients but confer an increased risk of cardiac dysfunction. Several strategies have been employed to help reduce anthracycline-induced cardiotoxicity, including pretreating the patient with the iron chelator dexrazoxane and infusing the dose of anthracycline over a longer period. Much focus has also been placed on the development of methods that decrease the toxicity of parent compounds, specifically through the use of drug carriers such as liposomes, and on the development of new, potentially less toxic anthracycline derivatives, such as amrubicin and pixantrone. We provide a review of these strategies, focusing on studies in pediatric patients when available, and support the idea that anthracycline therapy can be less cardiotoxic in pediatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.